FDA Approves DATROWAY® for Advanced HR+/HER2- Breast Cancer
Trop-2-directed antibody-drug conjugateA new breast cancer treatment option
The United States Food and Drug Administration (FDA) approved DATROWAY® (datopotamab deruxtecan-dlnk) on January 17, 2025, for adults with hormone receptor-positive (HR+), HER2-negative breast cancer that is unresectable or metastatic and has already been treated with both endocrine therapy and chemotherapy.
What is DATROWAY?
DATROWAY is a Trop-2-directed antibody-drug conjugate that delivers a chemotherapy payload directly to cancer cells. It was developed by Daiichi Sankyo, Inc.
Administration
DATROWAY is administered via IV infusion once every 3 weeks.
Clinical Trial Snapshot
- Trial Name: TROPION-Breast01
- Patients: 732 (across 20 countries; 59 from the U.S.)
- Design: Compared DATROWAY vs. chemotherapy
- Key Results:
- Progression-Free Survival (PFS):
- DATROWAY: 6.9 months
- Chemotherapy: 4.9 months
- Also showed improved response rates and duration of response.
Potential Side Effects
DATROWAY may cause:
- Severe lung problems, including life-threatening or fatal interstitial lung disease (ILD)
- Mouth sores, eye irritation, keratitis
- Risk to unborn babies
Most common side effects include:
- Mouth ulcers, nausea, fatigue
- Low white/red blood cell counts, hair loss
- Constipation, dry eyes, liver enzyme elevation
Summary
DATROWAY offers a new treatment option for patients with difficult-to-treat HR+/HER2- breast cancer, showing better cancer control than standard chemo — but it carries significant risks that must be carefully managed.
Editor’s Note: This is another in our series of potentially game-changing novel pharmaceuticals that FDA approved in 2024 and 2025. This approval report does not in any way recommend or promote this product. For more information contact your oncologist or the manufacturer. Report any adverse effects experienced with this product to FDA’s Medwatch System.
FDA – Do Not Use Non-piercing Devices to Measure Blood Glucose
FDA Safety Communication On February 21, 2024 the U.S. Food and Drug Administration (FDA) issued a safety communication regarding the use of smartwatches or smart rings that claim to measure blood glucose levels without the need for skin piercing. Its cautionary...
Medos International Recalls CEREBASE DA Guide Sheath
Urgent Class I Recall Notice Medos International Sàrl has issued an urgent recall for the Cerenovus CEREBASE DA Guide Sheath, a neurovascular catheter commonly used in procedures requiring precise navigation and access to blood vessels in the brain. The recall was...
Datex-Ohmeda Issues Field Correction for EVair Air Compressors
Urgent Class I Recall Notice Datex-Ohmeda Inc. has announced a field correction for its EVair and Jun-air compressors, optional ventilator accessories designed to provide an alternative source of airflow for patient support in clinical settings where wall air is...